Microsoft has discontinued support for Internet Explorer. To access the Tarter website, please install a modern browser like Microsoft Edge or Google Chrome.
This website does not track your personal or demographic information, only anonymous usage statistics. To ensure that you are not tracked, we have blocked all embedded content from third party sources like YouTube and SlideShare. Click "Accept Cookies" to enable third-party content. To learn more about our cookie policy,click here.
On May 8, 2020, the United States Patent and Trademark Office (USPTO) announced a new program for expediting certain COVID-19 related patent applications. Under the COVID-19 Prioritized Examination Pilot Program, the USPTO will grant requests for prioritized examination to small or micro entity status applicants without requiring payment of the typical prioritized examination fees. Also under this program, the USPTO will endeavor to reach final disposition of applications within six months if applicants are responsive.
To qualify for this program, the claims of the patent application must cover a product or process that is subject to U.S. Food and Drug Administration approval for use in the prevention or treatment of COVID-19.